Note: Table 21 columns are DARZALEX FASPRO (N=260) All Grades and Grade ≥3, then intravenous daratumumab (N=258) All Grades and Grade ≥3 (%). The last passage is from the Dosing and Administration Guide; the Darzalex HCP FAQ describes the same COLUMBA comparison as systemic administration-related reactions in 13% (n=260) vs 34% (n=258).
How common are infusion reactions with Darzalex IV?
Note: The Important Safety Information on the Darzalex HCP pages gives the multiple myeloma count in the systemic-reaction sentence as N=1235; the Prescribing Information gives N=1253.
Warnings
Can Darzalex cause eye problems such as acute myopia or angle-closure glaucoma?
Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the next four are from the DARZALEX FASPRO Prescribing Information. Table 8 (MAIA) columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). Table 10 (PERSEUS) columns are DARZALEX FASPRO-VRd All Grades and Grade 3 or 4, then VRd All Grades and Grade 3 or 4 (%).
Does Darzalex increase the risk of serious infections?
Note: The first passage is from the DARZALEX (intravenous) Prescribing Information; the second is from the DARZALEX FASPRO Prescribing Information, whose pooled population includes smoldering multiple myeloma and AL amyloidosis. The third passage is from the MAIA safety section of the DARZALEX Prescribing Information; the cumulative infection rates are from the follow-up safety analysis on the MAIA safety page.
Does Darzalex interfere with blood typing and transfusion tests?
Note: Table 7 columns are DRd (N=364) All Grades, Grade 3, and Grade 4, then Rd (N=365) All Grades, Grade 3, and Grade 4 (%). In the decreased appetite row, the label and the DRd All Grades value share one line. Table 8 columns follow the same order.
What are the side effects of Darzalex Faspro with VRd for transplant-ineligible patients (CEPHEUS)?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)
Note: Table 9 columns are DARZALEX FASPRO-VRd (N=351) All Grades and Grade 3 or 4, then VRd (N=347) All Grades and Grade 3 or 4 (%), through the end of consolidation.
How many patients stop Darzalex (DRd) because of side effects (MAIA)?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)
Note: The Safety Over Time page of the Darzalex HCP site reports, in a subset analysis by treatment duration (to approximately 30 months) that is not in the Prescribing Information, has not been evaluated by the FDA, and from which the page states no conclusions should be drawn, that 13% of intent-to-treat patients discontinued treatment due to a TEAE with DARZALEX + Rd (n=364) vs 22% with Rd alone (n=365).
What are the long-term side effects of Darzalex (DRd) in MAIA?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)
Note: The first four passages are from the follow-up safety analysis on the MAIA safety page; the last two are from the Safety Over Time page, whose subset analysis covers patients who continued treatment from treatment initiation to approximately 30 months. The most frequent TEAEs of the follow-up analysis appear on the page only as a figure.
What side effects have been reported with Darzalex since approval?